文献速递前列腺癌

多参数磁共振成像靶向穿刺联合系统穿刺前列腺活检无法避免系统穿刺

There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies.
PubMed 文献 · Eur Urol Oncol · 2019-03-27

该研究基于欧洲339例和北美441例接受融合MRI靶向穿刺联合经直肠超声引导系统穿刺的患者数据,旨在识别可避免系统穿刺的患者。多变量模型曲线下面积为0.78,但省略系统穿刺在风险阈值低于15%时并无净获益,研究未能找到可安全仅行靶向穿刺的患者。

要点

  • 在欧洲队列中,临床显著前列腺癌检出率为55%,系统穿刺检出率为41%。
  • 前列腺体积、既往阴性活检以及PI-RADS 4和5是靶点外临床显著前列腺癌的独立预测因素。
  • 基于多变量模型的预测概率阈值低于15%时省略系统穿刺无净获益,作者认为联合穿刺应强烈考虑为最佳方法。

核心结论

  • 研究未能识别出可安全仅接受MRI靶向穿刺的患者,联合靶向穿刺与系统穿刺应强烈考虑为最佳可用方法。

研究设计与样本

  • 研究纳入2013年至2017年间在欧洲和北美两家三级转诊中心接受融合MRI靶向穿刺联合经直肠超声引导系统穿刺的339例欧洲患者和441例北美患者。
  • 采用多变量逻辑回归分析建立预测靶点外临床显著前列腺癌的模型,并在每个队列中开发新的风险计算器。
  • 模型通过曲线下面积、校准图和决策曲线分析进行评估。

主要发现

  • 在欧洲队列中,临床显著前列腺癌检出率为55%,经直肠超声引导系统穿刺的临床显著前列腺癌检出率为41%。
  • 多变量分析显示,前列腺体积、既往阴性活检以及前列腺影像报告和数据系统第4版和第5版是靶点外临床显著前列腺癌的独立预测因素。
  • 多变量模型的曲线下面积为0.78。
  • 在计算风险低于15%的患者中省略经直肠超声引导系统穿刺可避免16%的系统穿刺,但代价是漏诊7%的临床显著前列腺癌。
  • 在北美队列中进行相同分析得到相似结果,两个队列中每个模型在低阈值概率(低于15%)下相对于标准治疗(对所有患者行MRI靶向穿刺联合系统穿刺)均未观察到净获益。

局限性

  • 研究受回顾性设计限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether or not adding systematic biopsies (transrectal ultrasound-guided biopsy [TRUS-Bx]) to targeted cores in patients with a lesion detected at multiparametric magnetic resonance imaging (mpMRI) is still a debated topic. OBJECTIVE: To identify patients who can avoid TRUS-Bx at the time of mpMRI targeted biopsy (MRI-TBx) relying on individual patient probability to harbour clinically significant prostate cancer (csPCa) outside the index lesion (IL). DESIGN, SETTING, AND PARTICIPANTS: A total of 339 European and 441 North American patients underwent fusion MRI-TBx and concomitant TRUS-Bx at two tertiary care referral centres between 2013 and 2017. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The study outcome was csPCa, defined as a Gleason score at biopsy of ≥7, outside the IL. Multivariable logistic regression analyses (MVAs) were performed to develop a predictive model for the study outcome. Multivariable-derived coefficients were used to develop a novel risk calculator in each cohort. The models were evaluated using the area under the curve (AUC), calibration plot, and decision-curve analyses. RESULTS AND LIMITATIONS: In the European cohort, csPCa detection rate was 55%. The csPCa detection rate for TRUS-Bx was 41%. At MVAs, prostate volume, previous negative biopsy, and Prostate Imaging Reporting and Data System versions 4 and 5 were independent predictors for the presence of csPCa outside the IL. The multivariable model had an AUC of 0.78. Omitting TRUS-Bx in patients with a calculated risk of <15% would have spared 16% of TRUS-Bx at the cost of missing 7% of csPCa. Similar findings were obtained when the same analyses were performed in the North American cohort. No net benefit was observed for low-threshold probabilities (<15%) of the each model relative to the standard of care (performing TRUS-Bx in addition to MRI-TBx to all patients) in both cohorts. The study is limited by its retrospective design. CONCLUSIONS: We failed to identify those patients who might safely benefit from MRI-TBx alone. The combination of MRI-TBx and TRUS-Bx should strongly be considered the best available approach. PATIENT SUMMARY: In the presence of positive multiparametric magnetic resonance imaging (mpMRI) of the prostate, physicians should always perform systematic sampling of the prostate in addition to mpMRI targeted biopsy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Dell'Oglio P, Stabile A, Soligo M, et al. There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies. Eur Urol Oncol. 2019. PMID: 31411973. doi:10.1016/j.euo.2019.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。